Afabicin
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2014 (NCT02162199)
Timeline
Indications
Mechanism of action
- Enoyl-ACP reductaseINHIBITOR
Q9BJJ9 inhibitor
Enoyl-[acyl-carrier-protein] reductase [NADPH] inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(CN(C)C(=O)/C=C/c2cnc3c(c2)CCC(=O)N3COP(=O)(O)O)oc2ccccc12- Mol. weight
- 485.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL4297501 ↗
Also known as
- debio 1450
- debio 1450 bes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03723551 | Phase 2 | Feb 20, 2019 | Debiopharm |
| NCT03209648 | Phase 1 | Jun 14, 2017 | Debiopharm |
| NCT02726438 | Phase 1 | Apr 1, 2016 | Debiopharm |
| NCT02595203 | Phase 1 | Nov 1, 2015 | Debiopharm |
| NCT02426918 | Phase 2 | May 1, 2015 | Debiopharm |
| NCT02214433 | Phase 1 | Aug 1, 2014 | Debiopharm |
| NCT02162199 | Phase 1 | Jun 1, 2014 | Debiopharm |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Debiopharm | For profit | 7 | 7 | 2 | 2014 |
1 organizations
Page 1 / 1